Liu et al. (2009) found APS-treated plasmacytoid DCs (pDC) secreted more IFN-α, IL-6, and TNF-α than the untreated group of CML patients at the remission phase, suggesting that APS can promote the function of pDC from CML. The gene discussed is IL6; the disease is autoimmune polyendocrinopathy.